POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Clinical trials for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new POORLY DIFFERENTIATED THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for POORLY DIFFERENTIATED THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cells from tumors could fight back against resistant cancers
Disease control OngoingThis study tests a treatment called LN-145, which uses a patient's own immune cells taken from their tumor. The cells are grown in a lab and then given back to the patient to help kill cancer cells. The study includes adults with ovarian cancer, triple-negative breast cancer, ana…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 16, 2026 22:50 UTC
-
New combo therapy shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tests whether the drug trametinib can make radioactive iodine treatment more effective for people with advanced thyroid cancer that has stopped responding to standard therapy. About 34 adults with certain genetic types of thyroid cancer will receive trametinib followed…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New drug combo shows promise for tough thyroid cancers
Disease control OngoingThis study tests whether a drug called PDR001, combined with either trametinib or dabrafenib, is safe and effective for people with thyroid cancer that no longer responds to radioactive iodine therapy. The trial includes 19 adults with certain types of advanced thyroid cancer. Re…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New drug shrinks thyroid tumors before surgery in early trial
Disease control OngoingThis study tests whether taking selpercatinib before surgery can shrink thyroid tumors that have a specific genetic change (RET alteration). About 30 people with advanced or recurrent thyroid cancer will receive the drug before their operation. The goal is to make surgery more ef…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New drug combo shows promise against aggressive thyroid cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with advanced anaplastic or poorly differentiated thyroid cancer live longer. About 50 participants will receive different drug combinations based on their cancer's geneti…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC
-
New drug combo shows promise against rare, aggressive thyroid cancer
Disease control OngoingThis study tests a combination of two drugs, lenvatinib and pembrolizumab, in 25 people with advanced anaplastic thyroid cancer that cannot be removed by surgery or has spread. Lenvatinib blocks enzymes that help cancer cells grow, while pembrolizumab helps the immune system atta…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
New drug cocktail shows promise for tough thyroid cancers
Disease control OngoingThis study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with a type of thyroid cancer that no longer responds to radioactive iodine and has worsened after one prior targeted therapy. The goal is to see if this mix can shrink tumors or slo…
Matched conditions: POORLY DIFFERENTIATED THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC